Articles

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

Onco-Hematology Dept., Hospital l’Archet, Nice, France
Lymphoid Malignancies Unit, Hospital Henri Mondor, Créteil, France
Hematology Dept., Hospital Béquerel, Rouen, France
Pathology Dept., Hospital Necker, Paris, France
Hematology Dept., Hospital Leon Berard, Lyon, France
Hematology Dept., Hospital Le Bocage, Dijon, France
Hematology Dept., Hospital Necker, Paris, France
Hematology Dept., Hospital Mont Godinne, Yvoir, Belgium
Medical Imaging Dept., Hospital Henri Mondor, Créteil, France
Pathology Dept., Hospital Le Bocage, Dijon, France
Hematology Dept., Hospital Mignot, Versailles, France
Hematology Dept., Hospital Brabois, Nancy, France
Hematology Dept., Hospital Lyon-Sud, Pierre Bénite, France
Medical Imaging Dept., Hospital Henri Mondor, Créteil, France
Pathology Dept., Hospital Henri Mondor, Créteil, France
Lymphoid Malignancies Unit, Hospital Henri Mondor, Créteil, France
Vol. 98 No. 11 (2013): November, 2013 https://doi.org/10.3324/haematol.2013.090597